<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Concern/Cancer_Prostate.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:30:31 GMT -->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1">
<meta name="Language" content="es">
<meta name="ContentID" content="1179002">
<meta name="Category" content="Concern">
<meta name="Article" content="Cancer_Prostate">
<title>C&#225;ncer de Pr&#243;stata-Referencias</title>
<link type="text/css" rel="stylesheet" href="../Styles/hnqrHtml.css">
<base target="_self">
</head>
<body>
<div id="Article-Title" class="Article-Title"><a name="Article-Title"></a> 

<p class="Article-Title">C&#225;ncer de pr&#243;stata</p>
</div>

<div id="Reference-List" class="Reference-List">
<p class="Reference-Autofill"><a href="Cancer_Prostate.htm">Volver al
art&#237;culo.</a></p>

<h3>Referencias para el art&#237;culo</h3>

<ol class="Reference-List">
<li class="Ref">Dennis LK. Meta-analysis for combining relative risks of alcohol consumption
and prostate cancer. <em>Prostate</em> 2000;42:56&#8211;66.</li>

<li class="Ref">Levy J, Bosin E, Feldman B, et al. Lycopene is a more potent inhibitor of
human cancer cell proliferation than either &#945;-carotene or &#946;-carotene. <em>Nutr
Cancer</em> 1995;24:257&#8211;66.</li>

<li class="Ref">Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review
of the epidemiologic literature. <em>J Natl Cancer Inst</em> 1999;91:317&#8211;31.</li>

<li class="Ref">Beecher CW. Cancer preventive properties of varieties of <em>Brassica
oleracea</em>: a review. <em>Am J Clin Nutr</em> 1994;59(suppl):1166&#8211;70S.</li>

<li class="Ref">Cover CM, Hsieh SJ, Cram EJ, et al. Indole-3-carbinol and tamoxifen cooperate
to arrest the cell cycle of MCF-7 human breast cancer cells. <em>Cancer Res</em>
1999;59:1244&#8211;51.</li>

<li class="Ref">Walaszek Z, Hanausek-Walaszek M, Minton JP, Webb TE. Dietary glucarate as
anti-promoter of 7,12-demethylbenz [a]anthracene-induced mammary tumorigenesis. <em>
Carcinogenesis</em> 1986;7:1463&#8211;6.</li>

<li class="Ref">Zhang Y, Kensler TW, Cho CG, et al. Anticarcinogenic activities of
sulforaphane and structurally related synthetic norbornyl isothiocyanates. <em>Proc Natl Acad
Sci USA</em> 1994;91:3147&#8211;50.</li>

<li class="Ref">Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate
cancer risk. <em>J Natl Cancer Inst</em> 2000;92(1):61&#8211;8.</li>

<li class="Ref">Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate
cancer risk. <em>J Natl Cancer Inst</em> 2000;92(1):61&#8211;8.</li>

<li class="Ref">Ghosh J, Myers C Jr. Arachidonic acid metabolism and cancer of the prostate.
<em>Nutrition</em> 1998;14:48&#8211;57 [editorial].</li>

<li class="Ref">Norrish AE, Ferguson LR, Knize MG, et al. Heterocyclic amine content of cooked
meat and risk of prostate cancer. <em>J Natl Cancer Inst</em> 1999;91:2038&#8211;44.</li>

<li class="Ref">Schuurman AG, van den Brandt PA, Dorant E, Goldohm RA. Animal products,
calcium and protein and prostate cancer risk in the Netherlands Cohort Study. <em>Br J
Cancer</em> 1999;80:1107&#8211;13.</li>

<li class="Ref">Kune GA. Eating fish protects against some cancers: epidemiological and
experimental evidence for a hypothesis. <em>J Nutr Med</em> 1990;1:139&#8211;44 [review].</li>

<li class="Ref">Rose DP, Connolley JM. Omega-3 fatty acids as cancer chemopreventive agents.
<em>Pharmacol Ther</em> 1999;83:217&#8211;44.</li>

<li class="Ref">Dorgan JF, Judd JT, Longcope C, et al. Effects of dietary fat and fiber on
plasma and urine androgens and estrogens in men: a controlled feeding study. <em>Am J Clin
Nutr</em> 1996;64:850&#8211;5.</li>

<li class="Ref">Peinta KJ, Esper PS. Is dietary fat a risk factor for prostate cancer? <em>J
Natl Cancer Inst</em> 1993;85:1538&#8211;9 [editorial/review].</li>

<li class="Ref">Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat
and risk of prostate cancer. <em>J Natl Cancer Inst</em> 1993;85:15571&#8211;9.</li>

<li class="Ref">Le Marchand L, Kolonel LN, Wilkens LR, et al. Animal fat consumption and
prostate cancer: a prospective study in Hawaii. <em>Epidemiology</em>
1994;5:276&#8211;82.</li>

<li class="Ref">Schuurman AG, van den Brandt PA, Dorant E, et al. Association of energy and
fat intake with prostate carcinoma risk: results from the Netherlands Cohort Study. <em>
Cancer</em> 1999;86:1019&#8211;27.</li>

<li class="Ref">Meyer F, Bairati I, Shadmani R, et al. Dietary fat and prostate cancer
survival. <em>Cancer Causes Control</em> 1999;10:245&#8211;51.</li>

<li class="Ref">Gann PH, Hennekens CH, Sacks FM, et al. Prospective study of plasma fatty
acids and risk of prostate cancer. <em>J Natl Cancer Inst</em> 1994;86:281&#8211;6.</li>

<li class="Ref">Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat
and risk of prostate cancer. <em>J Natl Cancer Inst</em>1993;85:1571&#8211;9.</li>

<li class="Ref">Harvei S, Bjerve KS, Tretli S, et al. Prediagnostic level of fatty acids in
serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. <em>Int
J Cancer</em> 1997;16:71:545&#8211;51.</li>

<li class="Ref">Schuurman AG, van den Brandt PA, Dorant E, et al. Association of energy and
fat intake with prostate carcinoma risk: results from the Netherlands Cohort Study. <em>
Cancer</em> 1999;86:1019&#8211;27.</li>

<li class="Ref">Gann PH, Hennekens CH, Sacks FM, et al. Prospective study of plasma fatty
acids and risk of prostate cancer. <em>J Natl Cancer Inst</em> 1994;86:281&#8211;6.</li>

<li class="Ref">Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat
and risk of prostate cancer. <em>J Natl Cancer Inst</em>1993;85:1571&#8211;9.</li>

<li class="Ref">Demark-Wahnefried W, Price DT, Polascik TJ, et al. Pilot study of dietary fat
restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring
the effects on hormonal levels, prostate-specific antigen, and histopathologic features. <em>
Urology</em>2001;58:47&#8211;52.</li>

<li class="Ref">Pandalai PK, Pilat MJ, Yamazaki K, et al. The effects of omega-3 and omega-6
fatty acids on in vitro prostate cancer growth. <em>Anticancer Res</em>
1996;16:815&#8211;20.</li>

<li class="Ref">De Toit PJ, van Aswegen CH, du Plessis DJ. The effect of essential fatty acids
on growth and urokinase-type plasminogen activator production in human prostate DU-145 cells.
<em>Prostaglandins Leuko Essent Fatty Acids</em> 1996;55:173&#8211;7.</li>

<li class="Ref">Davis JN, Singh B, Bhuiyan M, Sarkar FH. Genistein-induced upregulation of
p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. <em>
Nutr</em>&nbsp;<em>Cancer</em> 1998;32:123&#8211;31.</li>

<li class="Ref">Barnes S, Peterson TG, Coward L. Rationale for the use of genistein-containing
soy matrices in chemoprevention trials for breast and prostate cancer. <em>J Cell Biochem
Suppl</em> 1995;22:181&#8211;7.</li>

<li class="Ref">Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate
cancer incidence? The Adventist Health Study (United States). <em>Cancer Causes Control</em>
1998;9:553&#8211;7.</li>

<li class="Ref">Geller J, Sionit L, Partido C, et al. Genistein inhibits the growth of
human-patient BPH and prostate cancer in histoculture. <em>Prostate</em>
1998;34:75&#8211;9.</li>

<li class="Ref">Moyad MA. Soy, disease prevention, and prostate cancer. <em>Semin Urol
Oncol</em> 1999;17:97&#8211;102.</li>

<li class="Ref">Talamini R, La Vecchia C, Decarli A, et al. Nutrition, social factors and
prostatic cancer in a Northern Italian population. <em>Br J Cancer</em>
1986;53:817&#8211;21.</li>

<li class="Ref">Andersson S-O, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a
20-year follow-up study among 135,006 Swedish construction workers. <em>J Natl Cancer
Inst</em> 1997;89:385&#8211;9.</li>

<li class="Ref">Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation
with &#945;-tocopherol and &#946;-carotene: incidence and mortality in a controlled trial.
<em>J Natl Cancer Inst</em> 1998;90:440&#8211;6.</li>

<li class="Ref">Cook NR, Stampfer MJ, Ma J, et al. Beta-carotene supplementation for patients
with low baseline levels and decreased risks of total and prostate carcinoma. <em>Cancer</em>
1999;86:1783&#8211;92.</li>

<li class="Ref">Cook NR, Stampfer MJ, Ma J, et al. Beta-carotene supplementation for patients
with low baseline levels and decreased risks of total and prostate carcinoma. <em>Cancer</em>
1999;86:1783&#8211;92.</li>

<li class="Ref">Medina D. Mechanisms of selenium inhibition of tumorigenesis. <em>Adv Exp Med
Biol</em> 1986;206:465&#8211;72.</li>

<li class="Ref">Beisel WR. Single nutrients and immunity. <em>Am J Clin Nutr</em>
1982;35:417&#8211;68.</li>

<li class="Ref">Medina D, Morrison DG. Current ideas on selenium as a chemopreventative agent.
<em>Pathol Immunopathol Res</em> 1988;7:187&#8211;99.</li>

<li class="Ref">Shamberger RJ, Rukoven E, Lonfield AK, et al. Antioxidants and cancer. I.
Selenium in the blood of normals and cancer patients. <em>J Natl Cancer Inst</em>
1973;4:863&#8211;70.</li>

<li class="Ref">Willett WC, Polk BF, Morris JS, et al. Prediagnostic serum Selenium and risk
of cancer. <em>Lancet</em> 1983;42:130&#8211;4.</li>

<li class="Ref">Fex G, Pettersson B, Akesson B. Low plasma selenium as a risk factor for
cancer death in middle-aged men. <em>Nutr Cancer</em> 1987;10:221&#8211;9.</li>

<li class="Ref">Salonen J, Salonen R, Lappetelainen R, et al. Risk of cancer in relation to
serum concentrations of selenium and vitamins A and E; matched case-control analysis of
prospective data. <em>BMJ</em> 1985;290:417&#8211;20.</li>

<li class="Ref">Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation
for cancer prevention in patients with carcinoma of the skin. <em>JAMA</em>
1996;276:1957&#8211;63.</li>

<li class="Ref">Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation
for cancer prevention in patients with carcinoma of the skin. <em>JAMA</em>
1996;276:1957&#8211;63.</li>

<li class="Ref">Kucuk O, Sarkar FH, Sakr W, et al. Phase II randomized clinical trial of
lycopene supplementation before radical prostatectomy. <em>Cancer Epidemiol Biomarkers
Prev</em> 2001;10:861&#8211;8.</li>

<li class="Ref">Matlaga BR, Hall MC, Stindt D, Torti FM. Response of hormone refractory
prostate cancer to lycopene. <em>J Urol</em> 2001;166:613.</li>

<li class="Ref">Chan JM, Giovannucci E, Andersson S-O, et al. Dairy products, calcium,
phosphorus, vitamin D, and risk of prostate cancer (Sweden). <em>Cancer Causes Control</em>
1998;9:559&#8211;66.</li>

<li class="Ref">Giovannucci E, Rimm E, Wolk A, et al. Calcium and fructose intake in relation
to risk of prostate cancer. <em>Cancer Res</em> 1998;58:442&#8211;7.</li>

<li class="Ref">Yang CY, Chiu HF, Tsai SS, et al. Calcium and magnesium in drinking water and
risk of death from prostate cancer. <em>J Toxicol Environmental Health,</em> Part A
2000;60:17&#8211;26.</li>

<li class="Ref">Kristal AR, Stanford JL, Cohen JH, et al. Vitamin and mineral supplement use
is associated with reduced risk of prostate cancer. <em>Cancer Epidemiol Biomarkers Prev</em>
1999;8:887&#8211;92.</li>

<li class="Ref">Chan JM, Giovannucci E, Andersson S-O, et al. Dairy products, calcium,
phosphorus, vitamin D, and risk of prostate cancer (Sweden). <em>Cancer Causes Control</em>
1998;9:559&#8211;66.</li>

<li class="Ref">Hartman TJ, Dorgan JF, Virtamo J, et al. Association between serum
&#945;-tocopherol and serum androgens and estrogens in older men. <em>Nutr Cancer</em>
1999;35:10&#8211;5.</li>

<li class="Ref">Eicholzer M, St&#228;elin H, L&#252;din E, Bernasconi F. Smoking, plasma
vitamins C, E, retinol, and carotene, and fatal prostate cancer: seventeen-year follow-up of
the Prospective Basel Study. <em>Prostate</em> 1999;38:189&#8211;98.</li>

<li class="Ref">Hartman TJ, Albanes D, Pietinen P, et al. The association between baseline
vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer
prevention study. <em>Cancer Epidemiol Biomarkers Prev</em> 1998;7:335&#8211;40.</li>

<li class="Ref">Chan JM, Stampfer MJ, Ma J, et al. Supplemental vitamin E intake and prostate
cancer risk in a large cohort of men in the United States. <em>Cancer Epidemiol Biomarkers
Prev</em> 1999;8:893&#8211;9.</li>

<li class="Ref">Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation
with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. <em>J
Natl Cancer Inst</em> 1998;90:440&#8211;6.</li>

<li class="Ref">Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation
with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. <em>J
Natl Cancer Inst</em> 1998;90:440&#8211;6.</li>

<li class="Ref">Studzinski GP, Moore DC. Sunlight&#8211;&#8211;can it prevent as well as cause
cancer? <em>Cancer Res</em> 1995;55:4014&#8211;22 [review].</li>

<li class="Ref">Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM. Treatment of vitamin D
deficiency in patients with metastatic prostate cancer may improve bone pain and muscle
strength. <em>J Urol</em> 2000;163:187&#8211;90.</li>

<li class="Ref">Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM. Treatment of vitamin D
deficiency in patients with metastatic prostate cancer may improve bone pain and muscle
strength. <em>J Urol</em> 2000;163:187&#8211;90.</li>

<li class="Ref">Van Veldhuizen PJ, Taylor SA, Williamson S, Drees BM. Treatment of vitamin D
deficiency in patients with metastatic prostate cancer may improve bone pain and muscle
strength. <em>J Urol</em> 2000;163:187&#8211;90.</li>

<li class="Ref">Osborn JL, Schwartz GG, Smith DC, et al. Phase II trial of oral
1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. <em>Urol
Oncol</em> 1995;1:195&#8211;8.</li>

<li class="Ref">Giovannucci E. Dietary influences of 1,25(OH)2 vitamin D in relation to
prostate cancer: a hypothesis. <em>Cancer Causes Control</em> 1998;9:567&#8211;82.</li>

<li class="Ref">Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate
cancer with 1,25-dihydroxyvitamin D3 (calcitriol). <em>J Urol</em>
1998;159:2035&#8211;40.</li>

<li class="Ref">Lissoni P, Barni S, Crispino S, et al. Endocrine and immune effects of
melatonin therapy in metastatic cancer patients. <em>Eur J Cancer Clin Oncol</em>
1989;25:789&#8211;95.</li>

<li class="Ref">Neri B, De Leonardis V, Gemelli MT, et al. Melatonin as biological response
modifier in cancer patients. <em>Anticancer Res</em> 1998;18:1329&#8211;32.</li>

<li class="Ref">Lissoni P, Barni S, Crispino S, et al. Endocrine and immune effects of
melatonin therapy in metastatic cancer patients. <em>Eur J Cancer Clin Oncol</em>
1989;25:789&#8211;95.</li>

<li class="Ref">Lissoni P, Barni S, Ardizzoia A, et al. A randomized study with the pineal
hormone melatonin versus supportive care alone in patients with brain metastases due to solid
neoplasms. <em>Cancer</em> 1994;73:699&#8211;701.</li>

<li class="Ref">Lissoni P, Barni S, Ardizzoia A, et al. Randomized study with the pineal
hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant
to a first-line chemotherapy containing cisplatin. <em>Oncology</em> 1992;49:336&#8211;9.</li>

<li class="Ref">Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in
the treatment of neoplastic cachexia? <em>Eur J Cancer</em> 1996;32A:1340&#8211;3.</li>

<li class="Ref">Lissoni P, Barni S, Tancini G, et al. A randomised study with subcutaneous
low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in
advanced solid neoplasms other than renal cancer and melanoma. <em>Br J Cancer</em>
1994;69:196&#8211;9.</li>

<li class="Ref">Lissoni P, Brivio F, Ardizzoia A, et al. Subcutaneous therapy with low-dose
interlekin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low
performance status. <em>Tumori</em> 1993;79:401&#8211;4.</li>

<li class="Ref">Aldeghi R, Lissoni P, Barni S, et al. Low-dose interlekin-2 subcutaneous
immunotherapy in association with the pineal hormone melatonin as a first-line therapy in
locally advanced or metastatic hepatocellular carcinoma. <em>Eur J Cancer</em>
1994;30A:167&#8211;70.</li>

<li class="Ref">Lissoni P, Paolorossi F, Tancini G, et al. A phase II study of tamoxifen plus
melatonin in metastatic solid tumour patients. <em>Br J Cancer</em> 1996;74:1466&#8211;8.</li>

<li class="Ref">Lissoni P, Barni S, Mandal&#224;, et al. Decreased toxicity and increased
efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour
patients with poor clinical status. <em>Eur J Cancer</em> 1999;35:1688&#8211;92.</li>

<li class="Ref">Lissoni P, Brivio O, Brivio F, et al. Adjuvant therapy with the pineal hormone
melatonin in patients with lymph node relapse due to malignant melanoma. <em>J Pineal Res</em>
1996;21:239&#8211;42.</li>

<li class="Ref">Neri B, Fiorelli C, Moroni F, et al. Modulation of human lymphoblastoid
interferon activity by melatonin in metastatic renal cell carcinoma. <em>Cancer</em>
1994;73:315&#8211;9.</li>

<li class="Ref">Lissoni P, Cazzanga M, Tancini G, et al. Reversal of clinical resistance to
LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH
analogue plus melatonin in patients progressing on LHRH analogue alone. <em>Eur Urol</em>
1997;31:178&#8211;81.</li>

<li class="Ref">Lissoni P, Barni S, Mandal&#224;, et al. Decreased toxicity and increased
efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour
patients with poor clinical status. <em>Eur J Cancer</em> 1999;35:1688&#8211;92.</li>

<li class="Ref">William Judy, personal communication.</li>

<li class="Ref">William Judy, personal communication.</li>

<li class="Ref">Sheu JR, Fu CC, Tsai ML, Chung WJ. Effect of U-995, a potent shark
cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. <em>
Anticancer Res</em> 1998;18:4435&#8211;41.</li>

<li class="Ref">Lane IW, Contreras E Jr. High rate of bioactivity (reduction in gross tumor
size) observed in advanced cancer patients treated with shark cartilage material. <em>J
Naturopathic Med</em> 1992;3:86&#8211;8.</li>

<li class="Ref">Lane IW, Contreras E Jr. High rate of bioactivity (reduction in gross tumor
size) observed in advanced cancer patients treated with shark cartilage material. <em>J
Naturopathic Med</em> 1992;3:86&#8211;8.</li>

<li class="Ref">Milner M. Follow-up of cancer patients using shark cartilage. <em>Alternative
Complementary Ther</em> 1996;2:99&#8211;109.</li>

<li class="Ref">Miller DR, Anderson GT, Stark JJ, et al. Phase I/II trial of the safety and
efficacy of shark cartilage in the treatment of advanced cancer. <em>J Clin Oncol</em>
1998;16:3649&#8211;55.</li>

<li class="Ref">Miller DR, Anderson GT, Stark JJ, et al. Phase I/II trial of the safety and
efficacy of shark cartilage in the treatment of advanced cancer. <em>J Clin Oncol</em>
1998;16:3649&#8211;55.</li>

<li class="Ref">Costello LC, Franklin RB. Novel role of zinc in the regulation of prostate
citrate metabolism and its implications in prostate cancer. <em>Prostate</em>
1998;35:285&#8211;96.</li>

<li class="Ref">Liang JY, Liu YY, Zou J, et al. Inhibitory effect of zinc on human prostatic
cell growth. <em>Prostate</em> 1999;40:200&#8211;7.</li>

<li class="Ref">DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an
estrogenic herbal combination (PC-SPES) in prostate cancer. <em>New Engl J Med</em>
1998;339:785&#8211;91.</li>

<li class="Ref">Kameda H, Small EJ, Reese DM. A phase II study of PC-SPES, an herbal compound,
for the treatment of advanced prostate cancer (PCa). <em>Proc Am Soc Clin Oncol</em>
1999;18:320a [abstract].</li>

<li class="Ref">De la Taille A, Hayek OR, Buttyan R, et al. Effects of a phytotherapeutic
agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and
patients. <em>BJU Int</em> 1999;84:845&#8211;50.</li>

<li class="Ref">Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal
supplement PC-SPES in patients with progressive prostate cancer. <em>J Clin Oncol</em>
2000;18:3595&#8211;603.</li>

<li class="Ref">De la Taille A, Buttyan R, Hayek O, et al. Herbal therapy PC-SPES: in vitro
effects and evaluation of its efficacy in 69 patients with prostate cancer. <em>J Urology</em>
2000;164:1229&#8211;34.</li>

<li class="Ref">Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal
supplement PC-SPES in patients with progressive prostate cancer. <em>J Clin Oncol</em>
2000;18:3595&#8211;603.</li>

<li class="Ref">De la Taille A, Hayek OR, Buttyan R, et al. Effects of a phytotherapeutic
agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and
patients. <em>BJU Int</em> 1999;84:845&#8211;50.</li>

<li class="Ref">Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal
supplement PC-SPES in patients with progressive prostate cancer. <em>J Clin Oncol</em>
2000;18:3595&#8211;603.</li>

<li class="Ref">DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an
estrogenic herbal combination (PC-SPES) in prostate cancer. <em>New Engl J Med</em>
1998;339:785&#8211;91.</li>

<li class="Ref">DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an
estrogenic herbal combination (PC-SPES) in prostate cancer. <em>New Engl J Med</em>
1998;339:785&#8211;91.</li>

<li class="Ref">Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal
supplement PC-SPES in patients with progressive prostate cancer. <em>J Clin Oncol</em>
2000;18:3595&#8211;603.</li>

<li class="Ref">De la Taille A, Buttyan R, Hayek O, et al. Herbal therapy PC-SPES: in vitro
effects and evaluation of its efficacy in 69 patients with prostate cancer. <em>J Urology</em>
2000;164:1229&#8211;34.</li>

<li class="Ref">Strum SB. High risk prostate cancer. Prostate Cancer Research Institute Annual
Conference, July 31&#8211;August 1, 1999, Los Angeles, CA.</li>

<li class="Ref">Kameda H, Small EJ, Reese DM. A phase II study of PC-SPES, an herbal compound,
for the treatment of advanced prostate cancer (PCa). <em>Proc Am Soc Clin Oncol</em>
1999;18:320a [abstract].</li>

<li class="Ref">DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an
estrogenic herbal combination (PC-SPES) in prostate cancer. <em>New Engl J Med</em>
1998;339:785&#8211;91.</li>

<li class="Ref">Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal
supplement PC-SPES in patients with progressive prostate cancer. <em>J Clin Oncol</em>
2000;18:3595&#8211;603.</li>

<li class="Ref">De la Taille A, Buttyan R, Hayek O, et al. Herbal therapy PC-SPES: in vitro
effects and evaluation of its efficacy in 69 patients with prostate cancer. <em>J Urology</em>
2000;164:1229&#8211;34.</li>

<li class="Ref">Weinrobe MC, Montgomery B. Acquired bleeding diathesis in a patient taking
PC-SPES. <em>N Engl J Med</em> 2001;345:1213&#8211;4 [letter].</li>

<li class="Ref">Weinrobe MC, Montgomery B. Acquired bleeding diathesis in a patient taking
PC-SPES. <em>N Engl J Med</em> 2001;345:1213&#8211;4 [letter].</li>

<li class="Ref">Miyakoshi H, Aoki T, Mizukoshi M. Acting mechanism of lentinan in
human&#8212;II. Enhancement of non-specific cell-mediated cytotoxicity as an interferon
inducer. <em>Int J Immunopharmacol</em> 1984;6:373&#8211;9.</li>

<li class="Ref">Arinaga S, Karimine N, Takamuku K, et al. Enhanced induction of lymphokine
activated killer cell after lentinan administration in patients with gastric carcinoma. <em>
Int J Immunopharmacol</em> 1992;14:535&#8211;9.</li>

<li class="Ref">Matsuoka H, Yano K, Seo Y, et al. Usefulness of lymphocyte subset change as an
indicator for predicting survival time and effectiveness of treatment with the
immunopotentiator lentinan. <em>Anticancer Res</em> 1995;15:2291&#8211;6.</li>

<li class="Ref">Matsuoka H, Seo Y, Wakasugi H, et al. Lentinan potentiates immunity and
prolongs the survival time of some patients. <em>Anticancer Res</em>
1997;17:2751&#8211;6.</li>

<li class="Ref">Miyakoshi H, Aoki T, Mizukoshi M. Acting mechanism of lentinan in
human&#8212;II. Enhancement of non-specific cell-mediated cytotoxicity as an interferon
inducer. <em>Int J Immunopharmacol</em> 1984;6:373&#8211;9.</li>

<li class="Ref">Arinaga S, Karimine N, Takamuku K, et al. Enhanced induction of lymphokine
activated killer cell after lentinan administration in patients with gastric carcinoma. <em>
Int J Immunopharmacol</em> 1992;14:535&#8211;9.</li>

<li class="Ref">Matsuoka H, Yano K, Seo Y, et al. Usefulness of lymphocyte subset change as an
indicator for predicting survival time and effectiveness of treatment with the
immunopotentiator lentinan. <em>Anticancer Res</em> 1995;15:2291&#8211;6.</li>

<li class="Ref">Matsuoka H, Seo Y, Wakasugi H, et al. Lentinan potentiates immunity and
prolongs the survival time of some patients. <em>Anticancer Res</em>
1997;17:2751&#8211;6.</li>

<li class="Ref">Tari K, Satake I, Nakagomi K, et al. Effect of lentinan for advanced prostate
carcinoma. <em>Hinyokika Kiyo (Acta Urol Japon)</em> 1994;40:119&#8211;23 [in Japanese].</li>
</ol>
</div>
</body>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Concern/Cancer_Prostate.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:30:31 GMT -->
</html>

